On this page you can find relevant researchs on drug-related health topics, including HIV, hepatitis C, drug and overdose prevention, harm reduction and drug treatment. You can also find our Clinical Guidelines.

ANCD Position Statement: Expanding Naloxone Availability
A substantial body of evidence shows that expanding naloxone availability and training potential overdose witnesses to administer naloxone is a remarkably safe and effective intervention for preventing opioid overdose fatalities, with the potential to prevent opioid overdose related injury.
The Alternative World Drug Report: Counting the Costs of the War on Drugs
The Count the Costs initiative aims to highlight the negative impacts of the war on drugs in seven key policy areas: development and security; public health; human rights; stigma and discrimination; crime; the environment; and economics.
The Impact of Harm Reduction Programs on Law Enforcement in Southeast Asia: What Works and What Doesn’t
This Special Issue takes a pragmatic look at opportunities and barriers and it examines some of the factors that have determined the conflictual relationship between law enforcement and the protection of public health. It suggests that policing, when well conceived and implemented, actually constitutes a largely untapped resource in HIV prevention benefiting substance users and the rest of the population.
Supply, demand and harm reduction in Australian prisons - An update
Australia’s prisons currently have a major focus on reducing the supply of drugs with programs that are rarely evaluated and in the end fail to stop the availability or use of drugs in prisons.
Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers
With the arrival of simple, efficient and safe interferon-free treatment regimens, hepatitis C virus (HCV) therapy will have the potential to be successfully used for the majority of infected patients and prevent associated morbidity and mortality. With the current treatment uptake rates, only a very small proportion of HCV-infected patients are reached. Paradoxically, treatment rates are lowest in the most affected at-risk group – people who inject drugs (PWID) – which is the major driving force behind the spread of HCV infection.
IDHDP newsletter - Summer 2012
This issue highlights IDHDP activities, upcoming conferences, new publications, and more.
Chris Fords review on:A Quiet Revolution: drug decriminalisation policies in practice across the globe
Chris thinks about decriminalisation in response to Release’s report. We know criminalisation of individuals can impact them for the rest of their lives, affecting employment and education, not to mention their health and welfare. It stigmatises people and can push them further into the margins of society. As doctors, many of us may not have thought much about decriminalisation and its potential to improve the health and overall well-being of people who use drugs, but even for those of us who have, read this report: it is an eye opener.
Bridging The gap:Why the European Union must address the Global Fund’s funding crisis to tackle the escalating HIV and TB epidemics in Eastern Europe and Central Asia
The report calls on the EU to step in to fill the gaps left by global donors to countries within and neighbouring its borders.
EMCDDA guidelines for reporting data on people entering drug treatment in European countries
The EMCDDA guidelines have been revised to better reflect the realities of today’s drug situation and changes in treatment services and data monitoring systems. They follow a three-year revision process involving experts from the EU Member States, Croatia, Turkey, Norway and Switzerland.
Supply,demand and harm reduction strategies in Australian prisons an update
"This report provides an update of the 2004 study of supply, demand and harm reduction strategies in Australian prisons (Black, Dolan and Wodak, 2004). Since the 2004 report, the Ministerial Council on Drug Strategy (MCDS) launched the first National Corrections Drug Strategy in 2008, designed to guide the provision of supply, demand and harm reduction strategies in prisons throughout Australia (Ministerial Council on Drug Strategy, 2008)."
Share this on: